Role of pentraxin-3 in risk assessment of patients with metabolic syndrome.

Background: Inflammation plays a major role in the development of metabolic syndrome (MetS) and its progression. Recent studies have shown that pentraxin-3 (PTX-3), osteoprogerin (OPG), and tumor necrosis factor-alpha (TNF-α) are key factors in MetS pathophysiology, but evidence for endorsing their clinical use is currently unclear and insufficient.
Aim: The study aimed to evaluate the association between the inflammatory biomarkers' levels and the severity of MetS.
Methods: The study was observational, transversal, prospective, cohort, and analytical type. We enrolled 80 patients (M:F = 1, mean age = 55 ± 10.77 years) who met MetS criteria. The study protocol included: medical history, physical examination, 6-min walk test distance (6MWTD), biochemical tests, electrocardiogram, echocardiography, and carotid ultrasonography. We also performed plasmatic measurement of PTX-3, OPG, and TNF-α, in addition to standard biochemical tests.
Results: Subjects with severe MetS had higher values of body mass index (BMI) and waist circumference ( p  < 0.001, p  = 0.001). PTX-3 levels were significantly higher in patients with severe MetS ( p  = 0.03) and the values were not influenced by age or gender. OPG positively correlated with BMI ( r  = 0.264, p  = 0.018). 6MWTD was lower in patients with severe MetS ( p  = 0.005), whereas CCA-IMT was higher in this group of patients ( p  = 0.005). In addition, the receiver operating characteristic (ROC) curve analysis for PTX-3 identified a cut-off value of 10.7 ng/dl that differentiates between mild and severe MetS [AUC 0.656; sensitivity =47.1% (95% CI = 36.1%-62.3%); specificity = 78.9% (95% CI = 54.4%-93.9%)].
Conclusion: PTX-3 was correlated with the severity of MetS, with other inflammatory parameters and cardiovascular tests. CCA-IMT and 6MWTD are useful in differentiating between mild and severe MetS.